Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Pegfilgrastim-induced pain in patients with lymphoma.

Mullen EC.

Oncol Nurs Forum. 2014 Mar 1;41(2):212-4. doi: 10.1188/14.ONF.212-214. No abstract available.

PMID:
24578081
2.

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA.

Cancer. 2001 Jul 15;92(2):207-17.

PMID:
11466671
3.

Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.

Shin HJ, Chung JS, Song MK, Kim SK, Choe S, Cho GJ.

Cancer Chemother Pharmacol. 2012 May;69(5):1165-72. doi: 10.1007/s00280-011-1814-6. Epub 2012 Jan 4.

PMID:
22215473
4.
5.

Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.

Czuczman MS.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 3:S-46-52. No abstract available.

PMID:
23570100
6.

Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors.

Johnston KL, Farnen JP, Manske BR, Go RS.

Haematologica. 2005 Dec;90(12 Suppl):EIM03. No abstract available.

7.

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.

Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, D├╝hrsen U, Rossi FG, Schwenkglenks M, Bendall K, Szabo Z, Jaeger U.

Support Care Cancer. 2012 Mar;20(3):647-52. doi: 10.1007/s00520-011-1306-6. Epub 2011 Nov 20. Erratum in: Support Care Cancer. 2013 Feb;21(2):653. Johnson, Hans E [corrected to Johnsen, Hans E].

8.

Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.

Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.

Leuk Lymphoma. 2011 Nov;52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24.

PMID:
21702643
9.

Intravascular large B cell lymphoma: widespread but not everywhere.

Ponzoni M, Ferreri AJ.

Acta Haematol. 2014;131(1):16-7. doi: 10.1159/000354817. Epub 2013 Sep 10. No abstract available.

PMID:
24021531
10.

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

Fabbri A, Gozzetti A, Rigacci L.

Cancer. 2011 Aug 1;117(15):3530; author reply 3531. doi: 10.1002/cncr.25948. Epub 2011 Feb 1. No abstract available. Erratum in: Cancer. 2012 Jul 1;118(13):3446. Febbri, Alberto [corrected to Fabbri, Alberto].

11.

The clinical use of RHG-CSF for malignant lymphomas.

Oyama A, Suzuki H, Ogura M, Ariyoshi Y, Asano S.

J Nutr Sci Vitaminol (Tokyo). 1992;Spec No:361-4. No abstract available.

PMID:
1284307
12.

R-CHOP: does one size fit all in diffuse large B cell lymphoma?

Barnes JA, Abramson JS.

Acta Haematol. 2014;131(3):153-5. doi: 10.1159/000355325. Epub 2013 Nov 1. No abstract available.

13.

Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome.

Dozzo M, Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Mazzucco M, Perali G, Fanin R.

Am J Hematol. 2014 Oct;89(10):1011-3. doi: 10.1002/ajh.23783. Epub 2014 Jun 27. No abstract available.

14.

[Treatment of Burkitt lymphoma and Burkitt-like lymphoma].

Maruyama D.

Rinsho Ketsueki. 2011 Oct;52(10):1645-54. Review. Japanese. No abstract available.

PMID:
21971242
15.

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

Musolino A, Boggiani D, Panebianco M, Vasini G, Salvagni S, Franciosi V, Ardizzoni A.

Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.

16.

Pseudoleukemia after granulocyte colony-stimulating factor therapy.

Reale MA, Yen Y, Strair RK, Flynn SD, Cooper DL.

South Med J. 1995 Apr;88(4):462-4.

PMID:
7536347
17.

[Treatment strategy of gray zone lymphomas].

Maruyama D.

Rinsho Ketsueki. 2014 Oct;55(10):1912-9. Review. Japanese. No abstract available.

PMID:
25297755
18.

Front-line management of diffuse large B cell lymphoma.

Cabanillas F.

Curr Opin Oncol. 2010 Nov;22(6):642-5. doi: 10.1097/CCO.0b013e32833ed848. Review.

PMID:
20811278
19.

Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.

Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H, Kibbelaar RE, Veldhuis GJ, van Kamp H, van Rees B, Kluin-Nelemans HC, Veeger NJ, van Roon EN.

Br J Haematol. 2014 May;165(4):489-96. doi: 10.1111/bjh.12765. Epub 2014 Feb 7.

PMID:
24754632
20.

Intensified chemotherapy for diffuse large B-cell lymphomas.

Vose JM.

Lancet. 2011 Nov 26;378(9806):1828-9. doi: 10.1016/S0140-6736(11)61269-5. No abstract available.

PMID:
22118432

Supplemental Content

Support Center